🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Mizuho Securities Stick to Their Buy Rating for Merck & Company

Published 06/21/2020, 01:30 PM
MRK
-
HCSG
-
AZN
-


Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (NYSE:MRK) on Wednesday, setting a price target of $100, which is approximately 28.37% above the present share price of $77.9.

Goldstein expects Merck & Company to post earnings per share (EPS) of $1.27 for the second quarter of 2020.

The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Merck & Company, with an average price target of $92.1.
The analysts price targets range from a high of $100 to a low of $84.

In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $12.06 billion and a net profit of $3.98 billion. The company's market cap is $196.63 billion.

According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.7% and a 32.87% success rate.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services (NASDAQ:HCSG), and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca (NYSE:AZN) LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.